Akebia Therapeutics, Inc. AKBA

0.90 (0.02) (2.17%) as of 25 Sep
Market cap
$254.7M
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S ratio 1.75 2.50 1.22 0.39 1.77 1.32 2.23 1.54 3.59 0.00
P/FCF ratio 6.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 7.17
P/Operating CF 13.30 (89.74) (103.15) (2.07) (5.97) (12.59) (8.12) (4.35) (39.76) 4.14
P/B ratio 12.70 0.00 0.00 21.67 5.07 1.57 1.90 0.50 5.31 5.81
EV/Sales 1.25 2.53 1.18 0.30 1.94 0.88 2.03 1.11 1.84 0.00
EV/EBITDA 11.91 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/FCF 4.35 (9.96) (9.78) (1.21) (1.62) (2.30) (2.58) (2.33) (5.77) 2.46
Current Ratio 1.55 1.41 1.18 1.43 1.04 1.98 1.49 1.76 2.54 2.59
Net Debt/EBITDA (5.51) 1.02 0.96 0.57 (0.15) 0.56 0.27 0.51 4.21 1.92
Debt/Equity 1.48 (0.79) (1.13) 12.63 2.49 0.41 0.20 0.02 0.00 0.00
ROE 64.49% 174.03% 409.60% (237.83%) (175.37%) (119.82%) (54.27%) (37.86%) (77.27%) (136.35%)
ROA (1.79%) (30.02%) (17.37%) (21.28%) (48.07%) (54.38%) (31.64%) (21.10%) (22.17%) (61.26%)
ROIC 0.00% 0.00% 0.00% 0.00% (152.01%) (196.30%) (54.53%) (20.38%) 0.00% 0.00%
Return on Tangible Assets (5.86%) (197.65%) (237.01%) (154.82%) (1,673.53%) (199.49%) (250.15%) (68.18%) (33.36%) (73.51%)
Average Days of Receivables 72.68 78.31 73.69 50.27 88.95 82.81 42.61 410.54 68.91 8,042.60
Earnings Yield (1.06%) (17.37%) (22.05%) (82.26%) (75.22%) (98.93%) (37.34%) (44.67%) (12.76%) (34.29%)
Free Cash Flow Yield 16.39% (10.15%) (9.87%) (64.65%) (67.46%) (29.28%) (35.29%) (30.88%) (8.87%) 13.95%
Free Cash Flow per Share 0.26 (0.19) (0.12) (0.40) (1.52) (0.80) (2.23) (1.71) (1.33) 1.46
Book value per Share 0.13 (0.23) (0.16) 0.03 0.45 1.79 3.33 10.96 2.82 1.81
Free Cash Flow 67.87 (40.69) (23.38) (73.27) (253.02) (110.70) (264.10) (99.10) (57.78) 55.24
EV/EBIT 12.55 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates